c-MET (Y1230D)

MET · Variant type: point · HGVS: p.Y1230D

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	93.2%	6.8%	92.73
2	Crizotinib	92.1%	7.9%	91.39
3	Gilteritinib	88.3%	11.7%	88.97
4	Tivozanib	82.5%	17.5%	92.42
5	Pacritinib	74.4%	25.6%	88.64
6	Defactinib	61.3%	38.7%	92.68
7	Repotrectinib	52.1%	47.9%	84.21
8	Afatinib	51.5%	48.5%	98.50
9	Selpercatinib	48.0%	52.0%	96.72
10	Neratinib	45.6%	54.4%	93.18
11	Lenvatinib	36.8%	63.2%	97.74
12	Vemurafenib	35.5%	64.5%	96.49
13	Canertinib	35.4%	64.6%	96.49
14	Axitinib	34.5%	65.5%	93.23
15	Dacomitinib	33.4%	66.6%	97.99
16	Fedratinib	32.1%	67.9%	96.21
17	Sunitinib	24.3%	75.7%	91.73
18	Tepotinib	24.2%	75.8%	99.75
19	Fostamatinib	23.4%	76.6%	96.74
20	Capmatinib	23.2%	76.8%	99.75
21	Abemaciclib	23.1%	76.9%	91.48
22	Gefitinib	18.7%	81.3%	99.25
23	Erlotinib	16.4%	83.6%	99.75
24	Ripretinib	16.0%	84.0%	92.95
25	Ponatinib	15.8%	84.2%	78.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	93.2%	—	—
Crizotinib	92.1%	—	—
Gilteritinib	88.3%	—	—
Tivozanib	82.5%	—	—
Pacritinib	74.4%	—	—
Defactinib	61.3%	—	—
Repotrectinib	52.1%	—	—
Afatinib	51.5%	—	—
Selpercatinib	48.0%	—	—
Neratinib	45.6%	—	—
Lenvatinib	36.8%	—	—
Vemurafenib	35.5%	—	—
Canertinib	35.4%	—	—
Axitinib	34.5%	—	—
Dacomitinib	33.4%	—	—
Fedratinib	32.1%	—	—
Sunitinib	24.3%	—	—
Tepotinib	24.2%	—	—
Fostamatinib	23.4%	—	—
Capmatinib	23.2%	—	—
Abemaciclib	23.1%	—	—
Gefitinib	18.7%	—	—
Erlotinib	16.4%	—	—
Ripretinib	16.0%	—	—
Ponatinib	15.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms